265 related articles for article (PubMed ID: 3154307)
21. [Growth stimulating properties of angiotensin II on the heart: consequences for therapy of heart failure].
Schunkert H; Holmer SR; Riegger G
Z Kardiol; 1993; 82 Suppl 4():1-6. PubMed ID: 8147057
[TBL] [Abstract][Full Text] [Related]
22. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
Lim S
Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
[TBL] [Abstract][Full Text] [Related]
23. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
Brown NJ; Agirbasli M; Vaughan DE
Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin-converting enzyme inhibitors.
Herlihy BL; Herlihy JT
Crit Care Nurse; 1990 Mar; 10(3):74-7. PubMed ID: 2357893
[No Abstract] [Full Text] [Related]
25. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats.
Unger T; Ganten D; Lang RE; Schölkens BA
J Cardiovasc Pharmacol; 1984; 6(5):872-80. PubMed ID: 6209494
[TBL] [Abstract][Full Text] [Related]
26. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
27. [Alternative pathways of angiotensin I. The glimpse of new possibilities in the treatment of hypertension and heart failure].
Francischetti EA
Arq Bras Cardiol; 1995 Mar; 64(3):191-4. PubMed ID: 7487502
[No Abstract] [Full Text] [Related]
28. Specific properties and effect of perindopril in controlling the renin-angiotensin system.
Ferrari R; Pasanisi G; Notarstefano P; Campo G; Gardini E; Ceconi C
Am J Hypertens; 2005 Sep; 18(9 Pt 2):142S-154S. PubMed ID: 16125051
[TBL] [Abstract][Full Text] [Related]
29. Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure.
Su JB; Barbe F; Crozatier B; Campbell DJ; Hittinger L
J Cardiovasc Pharmacol; 1999 Nov; 34(5):700-10. PubMed ID: 10547087
[TBL] [Abstract][Full Text] [Related]
30. Pharmacologic management of heart failure: neurohormonal agents.
Moser DK
Crit Care Nurs Clin North Am; 1993 Dec; 5(4):599-608. PubMed ID: 7905275
[TBL] [Abstract][Full Text] [Related]
31. Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart.
Campbell DJ; Zhang Y; Kelly DJ; Gilbert RE; McCarthy DJ; Shi W; Smyth GK
Clin Exp Pharmacol Physiol; 2011 Sep; 38(9):623-31. PubMed ID: 21736602
[TBL] [Abstract][Full Text] [Related]
32. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
Carson PE
Am Heart J; 2000 Sep; 140(3):361-6. PubMed ID: 10966531
[TBL] [Abstract][Full Text] [Related]
33. Progress in the development of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Singh RK; Barker S
Curr Opin Investig Drugs; 2005 Mar; 6(3):269-74. PubMed ID: 15816503
[TBL] [Abstract][Full Text] [Related]
34. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
Cataliotti A; Boerrigter G; Chen HH; Jougasaki M; Costello LC; Tsuruda T; Lee SC; Malatino LS; Burnett JC
Circulation; 2002 Feb; 105(5):639-44. PubMed ID: 11827932
[TBL] [Abstract][Full Text] [Related]
35. [Angiotensin-converting enzyme inhibitors].
de Jong PE
Ned Tijdschr Geneeskd; 1988 Apr; 132(16):708-11. PubMed ID: 3374650
[No Abstract] [Full Text] [Related]
36. [Cardiovascular pharmacology (IX). Angiotensin-converting enzyme inhibitors in hypertension and heart failure].
de Teresa E; Espinosa JS; Gómez Doblas JJ
Rev Esp Cardiol; 1995 Feb; 48(2):128-41. PubMed ID: 7886264
[No Abstract] [Full Text] [Related]
37. Progress in angiotensin-converting enzyme inhibition in heart failure: rationale, mechanisms, and clinical responses.
Dzau VJ; Creager MA
Cardiol Clin; 1989 Feb; 7(1):119-30. PubMed ID: 2650868
[TBL] [Abstract][Full Text] [Related]
38. [Angiotensin-converting enzyme inhibitors in the treatment of heart failure: toward a change in the natural history of the disease].
Martín Luengo C; Arribas Jiménez A; Nieto Ballestero F; Diego Domínguez M; Cascón Bueno M; Pabón Osuna P; Sala Sánchez-Castillo A
Rev Esp Cardiol; 1993 Mar; 46(3):131-45. PubMed ID: 8488316
[No Abstract] [Full Text] [Related]
39. Angiotensin converting enzyme (ACE) inhibitors.
Antonaccio MJ
Annu Rev Pharmacol Toxicol; 1982; 22():57-87. PubMed ID: 6282189
[TBL] [Abstract][Full Text] [Related]
40. Common genetic variations of the renin-angiotensin-aldosterone system and response to acute angiotensin I-converting enzyme inhibition in essential hypertension.
Hannila-Handelberg T; Kontula KK; Paukku K; Lehtonen JY; Virtamo J; Tikkanen I; Hiltunen TP
J Hypertens; 2010 Apr; 28(4):771-9. PubMed ID: 20027122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
